<SEC-DOCUMENT>0001193125-25-136261.txt : 20250606
<SEC-HEADER>0001193125-25-136261.hdr.sgml : 20250606
<ACCEPTANCE-DATETIME>20250606060424
ACCESSION NUMBER:		0001193125-25-136261
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20250606
DATE AS OF CHANGE:		20250606

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYNAVAX TECHNOLOGIES CORP
		CENTRAL INDEX KEY:			0001029142
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				330728374
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34207
		FILM NUMBER:		251028763

	BUSINESS ADDRESS:	
		STREET 1:		2100 POWELL STREET
		STREET 2:		SUITE 720
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		5108485100

	MAIL ADDRESS:	
		STREET 1:		2100 POWELL STREET
		STREET 2:		SUITE 720
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d933807ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROXY
STATEMENT PURSUANT TO SECTION 14(a) OF THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the Registrant&#8194;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a Party other
than the Registrant&#8194;&#9744; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidential, for Use of the Commission Only (as permitted by Rule
<FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT> </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material Pursuant to <FONT STYLE="white-space:nowrap">&#167;240.14a-12</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Dynavax Technologies Corporation </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement if other than the Registrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee paid previously with preliminary materials. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rule
<FONT STYLE="white-space:nowrap">14a-6(i)(1)</FONT> and <FONT STYLE="white-space:nowrap">0-11.</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;5, 2025, Dynavax Technologies Corporation (the &#147;Company&#148;) submitted the attached
statement in response to a report issued by Glass, Lewis&nbsp;&amp; Co. on June&nbsp;3, 2025, relating to the Company&#146;s 2025 Annual Meeting of Stockholders. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g933807g0606033117828.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June 5, 2025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Re: Dynavax
2025 Annual Meeting of Stockholders Glass Lewis Report </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Dynavax Stockholders, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We appreciate the opportunity to respond directly to the recent Glass Lewis Report regarding Dynavax&#146;s upcoming Annual Meeting of Stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Glass Lewis&#146; report acknowledges that the Company&#146;s 2019 strategic pivot toward vaccines has driven meaningful stockholder value creation, with a
203% total return over the last five years<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> far outperforming peers and relevant indices. The report also recognizes the strength and depth of our Board, which has been significantly refreshed and
now includes directors with extensive, relevant expertise across vaccine development, commercialization and public company leadership. We firmly disagree with the report&#146;s conclusion, as the individuals Glass Lewis recommends against, Brent
MacGregor and Scott Myers, have been instrumental to the success the report acknowledges and bring critical experience and leadership that are essential to Dynavax&#146;s continued success and value creation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Glass Lewis&#146; recommendation seems rooted in a liquidity analysis that simply proves we have more cash than our peers; this fails to account for our
anticipated capital needs and interprets prudent capital allocation as excessive conservatism. The report also mistakenly characterizes our reluctance to grant direct board representation to an investor who we believe to be pursuing a
value-destructive strategy as insufficient responsiveness to stockholder feedback, which overlooks our concerted efforts to reach a reasonable compromise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Replacing any Dynavax directors with Deep Track&#146;s underqualified nominees would disrupt the momentum of our clearly successful long-term strategy and put
stockholder value at risk. As Glass Lewis notes, the skills Deep Track&#146;s candidates claim to offer are already <FONT STYLE="white-space:nowrap">well-represented</FONT> on our Board. Additionally, the report raises valid concerns about Brett
Erkman&#146;s lack of experience and rigid alignment with Deep Track&#146;s narrow agenda, which prioritizes short-term gain at the expense of long-term value. In addition, Donald Santel does not have any vaccine specific expertise, his public
C-suite experience ended ten years ago and his background is not additive to the skills of the existing Board or Mr.&nbsp;MacGregor or Mr.&nbsp;Myers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dynavax has the right strategy, the right leadership and a proven record of delivering results. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g933807g0606033118216.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ryan Spencer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive
Officer </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP> As of April 17, 2025, the date Dynavax filed its definitive proxy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2100 Powell Street, Suite 720, Emeryville, California 94608 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone: <FONT STYLE="white-space:nowrap">510-848-5100&#8195;Toll-Free:</FONT> 877-848-5100&#8195; Fax: 510-848-1327&#8195;www.dynavax.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g933807g0606033117828.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g933807g0606033117828.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  D /H# 2(  A$! Q$!_\0
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M*,J<_K-+=;^:"::?,C.\1_\ (P7GU3_T!:[NQ_Y!]M_UR7^0KS)F9V+.Q9B
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=.J)"BX@;"@;F0Y/N>:**\K">[7J)=_U,X_$S_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g933807g0606033118216.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g933807g0606033118216.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !  '$# 2(  A$! Q$!_\0
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:V>C-[BXD'_LE=#11<+#,R?W5_.BGT4AG_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
